Skip to main content

Table 1 Patient characteristics

From: Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis

  Study Overall
N = 934
  CECOG GET
vs FEC
N = 256
AGO
Mamma 1
N = 514
AGO
Mamma 3
N = 164
 
Age, years     
median (range) 53.5 (29-74) 56.0 (28-75) 58.0 (21-76) 56.0 (21-76)
  N % N % N % N %
HR status         
ER and/or PgR positive 118 67.43 324 69.83 131 80.37 573 71.45
missing 81   50   1   132  
Her2         
positive - - - - 30 23.08 30 23.08
missing 256   514   34   804  
Nodal status at first diagnosis         
positive 164 65.08 282 65.58 95 67.86 541 65.82
missing 4   84   24   112  
ECOG PS         
0 122 47.66 237 46.11 104 65.00 463 49.78
1 or 2 134 52.34 277 53.89 56 35.00 467 50.22
missing 0   0   4   4  
Prior chemotherapy         
none 126 49.22 325 63.98 96 58.54 547 58.94
non-anthracycline 130 50.78 162 31.89 34 20.73 326 35.13
anthracycline 0 0 21 4.13 34 20.73 55 5.93
missing 0   6   0   6  
Prior endocrine therapy         
yes 99 38.67 220 44.62 85 51.83 404 44.25
missing 0   21   0   21  
Metastatic site         
high-risk* 207 80.86 318 64.50 113 68.90 638 69.88
missing 0   21   0   21